Curasight A/s

Rigshospitalet

Trt Innovations Aps

Curasight Aps

Fluoguide A/s

Morten Persson

Andreas Kjaer

Jacob Madsen

Michael Ploug

There is provided a positron-emitting radionuclide labelled peptide for non-invasive PET imaging of the Urokinase-type Plasminogen Activator Receptor (uPAR) in humans. More specifically the invention relates to human uPAR PET imaging of any solid cancer disease for diagnosis, staging, treatment monitoring and especially as an imaging biomarker for predicting prognosis, progression and recurrence.

Positron emitting radionuclide labeled peptides for human uPAR PET imaging

There is provided a 177-Lu labelled peptide for site-specific targeting of the Urokinase Plasminogen Activator Receptor (uPAR) thereby enabling treatment of a cancer disease associated with high uPAR expression; e.g. treatment of colorectal cancer by administering to a patient an effective amount of the 177-Lu labelled peptide.

177-Lu labeled peptide for site-specific uPAR-targeting

There is provided a novel conjugate that binds to the cell surface receptor uPA (uPAR). The conjugate is based on a fluorescence-labeled peptide useful as a diagnostic probe to the surfaces of cells expressing uPAR. The conjugate is capable of carrying a suitable detectable and imageable label that will allow qualitative detection and also quantitation of uPAR levels in vitro and in vivo. This renders the surgical resection of tumors more optimal.

uPAR targeting peptide for use in peroperative optical imaging of invasive cancer

Growing community of inventors

Copenhagen, Denmark

Morten Persson